ST. LOUIS, Mo. (KMOX) – Good news for women with increased risk of breast cancer. St. Louis University Hospital breast surgeon, Dr. Teresa Schwartz, says she’s happy to see new ObamaCare guidelines that will cover the co-pay for some expensive breast cancer prevention drugs. The new prevention drugs are Tamoxifen and Reloxifeen.
“It’s only in certain patient populations and they really are the women at highest risk of getting breast cancer, but it definitely has a huge impact of their future breast cancer risk developments,” says Schwartz.
Previously until now, the co-pay for these two drugs were so high, some women could not afford to purchase them. Schwartz says with this new policy change, there should be no out-of-pocket expenses.
“This medication by itself, for this group women that are at a higher risk, does make a tremendous improvement in their risk of getting breast cancer down the line,” says Schwartz.
She says that this could the difference between life and death. In some cases there can be up to a 45% risk reduction.